- Home
- MDGL vs BBIO Comparison
MDGL vs BBIO Comparison
Compare MDGL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BBIO
- Stock Information
- Founded
- MDGL 2011
- BBIO 2015
- Country
- MDGL United States
- BBIO United States
- Employees
- MDGL N/A
- BBIO N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- BBIO Health Care
- Exchange
- MDGL Nasdaq
- BBIO Nasdaq
- Market Cap
- MDGL 6.8B
- BBIO 6.7B
- IPO Year
- MDGL N/A
- BBIO 2019
- Fundamental
- Price
- MDGL $275.26
- BBIO $34.25
- Analyst Decision
- MDGL Strong Buy
- BBIO Strong Buy
- Analyst Count
- MDGL 10
- BBIO 12
- Target Price
- MDGL $420.63
- BBIO $57.09
- AVG Volume (30 Days)
- MDGL 335.5K
- BBIO 2.9M
- Earning Date
- MDGL 05-01-2025
- BBIO 04-29-2025
- Dividend Yield
- MDGL N/A
- BBIO N/A
- EPS Growth
- MDGL N/A
- BBIO N/A
- EPS
- MDGL N/A
- BBIO N/A
- Revenue
- MDGL $317,383,000.00
- BBIO $127,415,000.00
- Revenue This Year
- MDGL $285.43
- BBIO $89.10
- Revenue Next Year
- MDGL $63.77
- BBIO $57.07
- P/E Ratio
- MDGL N/A
- BBIO N/A
- Revenue Growth
- MDGL N/A
- BBIO N/A
- 52 Week Low
- MDGL $200.63
- BBIO $21.62
- 52 Week High
- MDGL $377.46
- BBIO $39.54
- Technical
- Relative Strength Index (RSI)
- MDGL 38.56
- BBIO 50.58
- Support Level
- MDGL $265.39
- BBIO $31.77
- Resistance Level
- MDGL $275.54
- BBIO $33.93
- Average True Range (ATR)
- MDGL 11.39
- BBIO 1.28
- MACD
- MDGL -1.08
- BBIO -0.09
- Stochastic Oscillator
- MDGL 24.12
- BBIO 57.14
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.